By in

Exercise of Options (3 September 2019)

Press Release
3rd September 2019

Sativa Group PLC
(“Sativa” or “the Company” or “the Group”)
Exercise of Options

Sativa Group Plc (NEX: SATI), announces that it has allotted 7,000,000 new ordinary shares of 0.25 pence each in the Company (“Ordinary Shares”) pursuant to the exercise of share options.  Application has been made for the new Ordinary Shares to be admitted to trading on the NEX Exchange Growth Market (“Admission”) and Admission is expected to become effective on 9 September 2019.

The option holder has exercised 7,000,000 options with an exercise price of 0.5p.  Gross proceeds of £35,000 have been received by the Company and will be used for general working capital purposes.  The option holder is restricted from disposing of shares or any interest in shares until 30 August 2020 without the approval of Cenkos Securities, the Company’s Corporate Adviser.  

The new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.  

Following Admission, the Company’s issued share capital will comprise 534,689,167 Ordinary Shares, which number may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.  The Company does not hold any shares in treasury.

 

For further information please contact:

Henry Buckley
Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

NEX Exchange Corporate Adviser
Corporate Finance
Stephen Keys / Max Gould Cenkos Securities plc
+44 (0) 20 7397 8900

Equity Sales
Julian Morse
Cenkos Securities +44 (0) 20 7397 8900

Financial PR and IR
Julian Bosdet
Abchurch Communications
+44 (0) 7771 663 886
SativaInvestments@abchurch-group.com

Joseph Colliver
Chief Financial Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk



Notes to Editors

Sativa is a seed to Consumer medicinal cannabis and cannabidiol (CBD) wellness business, focused on the smart-sourcing of the raw material, advanced extraction, manufacture, testing, distribution, and research & development of medicinal cannabis and CBD products. The Company has a Home Office licence application in process which, when granted as the Directors believe it will be as the application is in its final stages, will enable the Company to engage in the highly regulated process of growing, strictly for medicinal research & development purposes only, Tetrahydrocannabinol (THC) rich cannabis flowers at its high- security Somerset headquarters.

The Company joined the UK’s NEX market in March 2018 as the UK’s first medicinal cannabis investment vehicle and since then has capitalised on its first-mover advantage, developing a substantial UK bridgehead into what the Company believes will be a significant market in the future. Two UK operating subsidiaries, PhytoVista Laboratories and George Botanicals, are already well established and fully trading with healthy gross margins in independent CBD testing and CBD wholesale & retail respectively.

Phytovista has conducted over 1000 independent tests and George Botanicals develops, manufactures and distributes low-THC CBD wellness products. Other important future revenue streams are at various stages of development from concept to actual launch, with the first Goodbody CBD wellness centre opening in Bath on 28th June.

Prior to the Listing, Sativa’s founder and CEO, Geremy Thomas, spent 12 months researching the global medical cannabis and CBD industries at his own personal expense. He based himself in Canada, the most advanced country in terms of medicinal cannabis acceptance and regulation, travelling to America, Australia, the Far East, and Europe to connect with industry leaders and participants. The Company on Listing was therefore already internationally connected, and this has given it a head start within the UK industry for smart-sourcing and the adoption of advanced value-add techniques and models.

In May 2019 the Company obtained permission from NEX Exchange to reclassify itself as a trading company, having delivered on its original investment strategy. Benefits of this include widening the appeal of the equity opportunity to additional types of investors including institutions and family offices, many of which are precluded from investing in fund-type vehicles.

Sativa has a highly experienced Medical Advisory Board, Chaired by Sir Alasdair Breckenridge, a former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA). He is joined by Dr Matthew Brown, an award-winning pain consultant at The Royal Marsden Hospital, Dr. Peter Fedlshreiber, a barrister and physician specialising in medical law, and Dr. Stuart Ungar, co-founder of the Doctors Laboratory and who researched biochemical neuropsychopharmacology at the Royal Free Hospital.

The Company has a strong senior management team and Board team including Joseph Colliver FCA as Chief Financial Officer and a Board Director, and Jonathan Wearing, a seasoned City corporate financier, as Chairman. Dr Nick Horniman, Director of Regulatory Affairs, has over thirty years of experience in the veterinary industry and he co-ordinates the Group’s ongoing relationships with regulators such as the Home Office, Food Standards Agency (FSA) and the Veterinary Medicines Directorate (VMD). He is also investigating the significant opportunities for medicinal cannabis and CBD products in the pet and equine markets. Chris Jones, a retail management professional who was instrumental in building the Phones 4U chain, leads the team developing the Goodbody wellness centres, which will offer customers a variety of high-quality CBD products.

Sativa’s smart-sourcing strategy enables it to define the crucial factors of seed strain, growing techniques and environment, along with extraction methods, all of which are imperative to the quality of the end-product. Phytovista Laboratories confirms the cannabinoid profile and quality of each batch on delivery to ensure that it is regulatorily compliant, is free of unwanted chemical elements, and is of proven origin. The commercial off-take agreements that the Company is entering in to will contribute to quality assurance, forecasted forward quantities of supply, consistency, and pre-determined pricing, rather than spot pricing.

The Group’s activities include the Sativa Foundation, which awards research grants to academic institutions in order to further research & development into the efficacy of the full spectrum of cannabinoids. In April 2019 the Company entered into a three-year research agreement with King’s College London to research the impact of cannabinoids on inflammation and respiratory diseases.

Sativa has invested in two Canadian-based businesses, pharmaceutical company Veritas Pharma Inc. and a Rapid Dose Therapeutics Inc. Both of these provide Sativa with valuable know-how alongside their investment potential. The Company also has a 60% share of a joint venture with Germany’s Lexamed GmbH, providing a foothold into the German market.

For more information on Sativa Investments, please visit: www.sativagroup.co.uk

– Ends –

By in

Sativa completes initial phase of Goodbody CBD Wellness store chain, opening its third store and advancing to franchise roll-out

Press Release
28th August 2019

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Group PLC
(“Sativa” or “the Company” or “the Group”) 

Sativa completes initial phase of Goodbody CBD Wellness store chain,

opening its third store and advancing to franchise roll-out

 
 

Sativa Group Plc [NEX: SATI], the UK’s leading quoted CBD Wellness and medicinal cannabis Group, has completed the initial phase of its Goodbody CBD Wellness store chain, choosing Clifton, Bristol as the third and final location for proof-of-concept, alongside Bath and Cirencester.  The Group is now actively seeking franchisees to participate in its comprehensive, full-support national franchise plan. 

The 500 sq ft (45.5 sq. m.) Queens Road store joins Space NK, Waitrose, The White Stuff, Café Nero, Vodafone and Wagamma in the Clifton Triangle, a thriving and vibrant primary retail destination.  The store stocks a range of more than 50 CBD products and each store has a tasting bar for customers to sample CBD products and enjoy a cup of high quality CBD infused coffee. 

The consumer experience consists of focused knowledge and support from highly trained staff who are able to advise customers on the range of CBD products available and the best way to use and apply those products.  CBD is believed to boost the body’s endo-cannabinoid system which works to restore homeostasis and balance.  CBD enriched products available include skincare, tinctures, balms, bath bombs, vape oils, body oils and capsules. 

Chris Jones, Managing Director of Goodbody Wellness, said: “It was a great launch weekend with customer feedback echoing the sentiments given about the first two stores.  The customers really appreciate a prestige high-street brand which they can trust.  It’s all about traceability, product testing, and balance. 

“A welcome surprise was that the store opened for business a day early. We hadn’t even switched on the digital display boards and customers were knocking on the door.  That gave the team an early chance to put their extensive training in to practice.  Our fellow traders in the Clifton Triangle have been highly complimentary about our store design and quality of product and Goodbody is already viewed as a further boost to local high-street retail.”

Recently-appointed Sativa CEO Henry Lees-Buckley said: “Goodbody has achieved this significant milestone in just eight months.  It’s an important third CBD trading business to the Group alongside George Botanicals and our direct CBD marketing channel, and a fellow Group subsidiary to PhytoVista Laboratories. 

“We expect to soon add the licenced growing of medicinal cannabis, once necessary approvals are in place, for research and development purposes through our collaboration agreement with Kings College London, which is looking at the potential benefits that medicinal cannabis might have on respiratory diseases.” 

The Company has a full-scale replica Goodbody store at its Somerset headquarters alongside its bespoke training facility.  All three trading stores are within an hour’s drive, allowing potential franchisees to absorb the concept and then witness it trading first-hand.

Goodbody Managing Director Chris Jones is a highly experienced international retail expert, as detailed in his appointment release of 15th January 2019.

High resolution photographs of the stores are available from Yoko@goodbodywellness.co.uk

 

For further information please contact:

Chris Jones

Managing Director 

Goodbody Wellness

 

Henry Lees-Buckley 

Chief Executive Officer 

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

NEX Exchange Corporate Adviser
Corporate Finance
Stephen Keys / Max Gould Cenkos Securities plc
+44 (0) 20 7397 8900

Equity Sales
Julian Morse
Cenkos Securities +44 (0) 20 7397 8900

Financial PR and IR
Julian Bosdet
Abchurch Communications
+44 (0) 7771 663 886 SativaInvestments@abchurch-group.com

Joseph Colliver

Chief Financial Officer

Notes to Editors

Sativa is a seed to Consumer CBD Wellness and medicinal cannabis business, focused on the smart-sourcing of the raw material, advanced extraction, manufacture, testing, distribution, and research & development of medicinal cannabis and CBD products.  The Company has a Home Office licence application in process which, when granted as the Directors believe it will be as the application is in its final stages, will enable the Company to engage in the highly regulated process of growing, strictly for medicinal research & development purposes only, Tetrahydrocannabinol (THC) rich cannabis flowers at its high-security Somerset headquarters. 

The Company joined the UK’s NEX market in March 2018 as the UK’s first medicinal cannabis investment vehicle and since then has capitalised on its first-mover advantage, developing a substantial UK bridgehead into what the Company believes will be a significant market in the future.  Two UK operating subsidiaries, PhytoVista Laboratories and George Botanicals, are already well established and fully trading with healthy gross margins in independent CBD testing and CBD wholesale & retail respectively.  

Phytovista has conducted over 1000 independent tests and George Botanicals develops, manufactures and distributes low-THC CBD wellness products.  Other important future revenue streams are at various stages of development from concept to actual launch, with two Goodbody Wellness centres open in Bath and Bristol. 

Prior to the Listing, Sativa’s founder and Deputy Chairman, Geremy Thomas, spent 12 months researching the global medical cannabis and CBD industries at his own personal expense.  He based himself in Canada, the most advanced country in terms of medicinal cannabis acceptance and regulation, travelling to America, Australia, the Far East, and Europe to connect with industry leaders and participants.  The Company on Listing was therefore already internationally connected, and this has given it a head start within the UK industry for smart-sourcing and the adoption of advanced value-add techniques and models. 

In May 2019 the Company obtained permission from NEX Exchange to reclassify itself as a trading company, having delivered on its original investment strategy.  Benefits of this include widening the appeal of the equity opportunity to additional types of investors including institutions and family offices, many of which are precluded from investing in fund-type vehicles. 

– Ends –

By in

Sativa appoints Henry Lees-Buckley CEO as business develops

Press Release
19th August 2019

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Group PLC
(“Sativa” or “the Company” or “the Group”) 
Sativa appoints Henry Lees-Buckley CEO as business develops
 
 

Sativa Group Plc [NEX: SATI], the UK’s leading quoted CBD Wellness and medicinal cannabis Group, is pleased to announce it has appointed Henry Lees-Buckley as Chief Executive Officer and a Director of the Company with immediate effect.  Henry was previously CEO of Uni-Select [TSX:UNS], a Canadian TSX quoted company, with operations in the UK, Canada and the USA.  Prior to that he was a senior global executive and officer in the USA and Canada for W.W. Grainger, a US$15 billion Fortune 500 company.  Henry is currently a non-Executive Director of NASDAQ-quoted BMC (Building Materials Corp) [NASDAQ:BMCH] which has sales of US$3.8 billion and a market capitalisation of US$1.6 billion. 

Henry, who holds dual United Kingdom and Canadian citizenship, has held numerous executive level positions both in North America and also the United Kingdom.  He holds an MBA from Queens University, Kingston, Ontario, has moved to the United Kingdom, and from now will operate from Sativa’s Somerset headquarters. 

Sativa’s founder and current Chief Executive Officer Geremy Thomas will transition to the role of Deputy Chairman with immediate effect and will continue to deliver to the Group his significant knowledge and expertise in the medicinal cannabis industry.  Geremy said: “Henry’s appointment is a clear statement of the Board’s ambition for the Group.  Henry has the enthusiasm, expertise and experience to grow the business significantly.  “His experience of major capital market businesses, executive leadership and M&A will be of great use as the Company seeks to accelerate both organic and acquisitive growth and attract a broader investor base including institutions. Appropriate capital markets remain a focus for the Group.” 

Newly appointed Henry Lees-Buckley said: “Sativa has made remarkable advances in its first 18 months as a quoted vehicle and I am looking forward to working with the team to build on this foundation and guide and grow the business moving forward.  The UK market is particularly exciting as it is adopting already globally proven interest in CBD wellness and medicinal cannabis products.  This provides a significant runway ahead for us and, as Sativa operates in a complex and heavily regulated industry, management strength and controls are key.” 

The past and current directorships of Henry Lees-Buckley are:

Current

Previous

  • BMC Stock Holdings Inc
  • Uni-Select USA Inc
  • FinishMaster Inc
  • Uni-Select Inc
  • Uni-Select Canada Stores Inc
  • FinishMaster Inc
  • Uni-Select Quebec Inc
  • Uni-Select Pacific Inc
  • Acklands Grainger Inc
  • Canwel Building Materials Ltd
  • Buckley’s Office Service Centre Inc
  • Car Part World Limited
  • URO (South West) Limited
  • URO Auto Spares |Limited
  • 121333 Limited
  • 121222 Holdco Limited
  • Allparts Bidco Limited
  • BMS Superfactors Limited
  • CES Bidco Limited
  • Data Development Services Limited
  • DDS Midco Limited
  • German Swedish & French Car Parts Limited
  • GMF Bidco Limited
  • PA Group Holdings Limited
  • PA Topco Limited
  • Parts Alliance Group Limited
  • SCMF Bidco Limited
  • Superfactor (Holdings) Limited
  • The Parts Alliance Limited
  • Beckwith Ltd
  • S A S Autoparts Ltd
  • Waterloo (Motor Trade) Holdings Limited
  • Waterloo (Motor Trade) Limited
  • Blackburn Brakes Holdings Limited
  • BBC Superfactors Ltd

For further information please contact:

Geremy Thomas

Founder & Deputy Chairman 

 

Henry Lees-Buckley 

Chief Executive Officer 

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

NEX Exchange Corporate Adviser
Corporate Finance
Stephen Keys / Max Gould Cenkos Securities plc
+44 (0) 20 7397 8900

Equity Sales
Julian Morse
Cenkos Securities +44 (0) 20 7397 8900

Financial PR and IR
Julian Bosdet
Abchurch Communications
+44 (0) 7771 663 886 SativaInvestments@abchurch-group.com

Joseph Colliver

Chief Financial Officer

 

Notes to Editors

Sativa is a seed to Consumer CBD Wellness and medicinal cannabis business, focused on the smart-sourcing of the raw material, advanced extraction, manufacture, testing, distribution, and research & development of medicinal cannabis and CBD products.  The Company has a Home Office licence application in process which, when granted as the Directors believe it will be as the application is in its final stages, will enable the Company to engage in the highly regulated process of growing, strictly for medicinal research & development purposes only, Tetrahydrocannabinol (THC) rich cannabis flowers at its high-security Somerset headquarters. 

The Company joined the UK’s NEX market in March 2018 as the UK’s first medicinal cannabis investment vehicle and since then has capitalised on its first-mover advantage, developing a substantial UK bridgehead into what the Company believes will be a significant market in the future.  Two UK operating subsidiaries, PhytoVista Laboratories and George Botanicals, are already well established and fully trading with healthy gross margins in independent CBD testing and CBD wholesale & retail respectively.  

Phytovista has conducted over 1000 independent tests and George Botanicals develops, manufactures and distributes low-THC CBD wellness products.  Other important future revenue streams are at various stages of development from concept to actual launch, with two Goodbody Wellness centres open in Bath and Bristol. 

Prior to the Listing, Sativa’s founder and Deputy Chairman, Geremy Thomas, spent 12 months researching the global medical cannabis and CBD industries at his own personal expense.  He based himself in Canada, the most advanced country in terms of medicinal cannabis acceptance and regulation, travelling to America, Australia, the Far East, and Europe to connect with industry leaders and participants.  The Company on Listing was therefore already internationally connected, and this has given it a head start within the UK industry for smart-sourcing and the adoption of advanced value-add techniques and models. 

In May 2019 the Company obtained permission from NEX Exchange to reclassify itself as a trading company, having delivered on its original investment strategy.  Benefits of this include widening the appeal of the equity opportunity to additional types of investors including institutions and family offices, many of which are precluded from investing in fund-type vehicles. 

 

– Ends –

By in , ,

INTERVIEW: Sativa Group ‘A Big Boost’ from Health Secretary’s Statement

Sativa Group (NEX: SATI) CEO Geremy Thomas joins DirectorsTalk to comment on the statement made by Health Secretary Matt Hancock. Geremy also explains the significance of appointing new broker Cenkos.

Sativa is a seed to Consumer medicinal cannabis and cannabidiol (CBD) wellness business, focused on the smart-sourcing of the raw material, advanced extraction, manufacture, testing, distribution, and research & development of medicinal cannabis and CBD products. The Company has a Home Office licence application in process which, when granted as the Directors believe it will be as the application is in its final stages, will enable the Company to engage in the highly regulated process of growing, strictly for medicinal research & development purposes only, Tetrahydrocannabinol (THC) rich cannabis flowers at its high-security Somerset headquarters.

The Company joined the UK’s NEX market in March 2018 as the UK’s first medicinal cannabis investment vehicle and since then has capitalised on its first-mover advantage, developing a substantial UK bridgehead into what the Company believes will be a significant market in the future. Two UK operating subsidiaries, PhytoVista Laboratories and George Botanicals, are already well established and fully trading with healthy gross margins in independent CBD testing and CBD wholesale & retail respectively.

Phytovista has conducted over 1000 independent tests and George Botanicals develops, manufactures and distributes low-THC CBD wellness products. Other important future revenue streams are at various stages of development from concept to actual launch, with the first Goodbody CBD wellness centre opening in Bath on 28th June.

Prior to the Listing, Sativa’s founder and CEO, Geremy Thomas, spent 12 months researching the global medical cannabis and CBD industries at his own personal expense. He based himself in Canada, the most advanced country in terms of medicinal cannabis acceptance and regulation, travelling to America, Australia, the Far East, and Europe to connect with industry leaders and participants. The Company on Listing was therefore already internationally connected, and this has given it a head start within the UK industry for smart-sourcing and the adoption of advanced value-add techniques and models.

In May 2019 the Company obtained permission from NEX Exchange to reclassify itself as a trading company, having delivered on its original investment strategy. Benefits of this include widening the appeal of the equity opportunity to additional types of investors including institutions and family offices, many of which are precluded from investing in fund-type vehicles.

Sativa has a highly experienced Medical Advisory Board, Chaired by Sir Alasdair Breckenridge, a former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA). He is joined by Dr Matthew Brown, an award-winning pain consultant at The Royal Marsden Hospital, Dr. Peter Fedlshreiber, a barrister and physician specialising in medical law, and Dr. Stuart Ungar, co-founder of the Doctors Laboratory and who researched biochemical neuropsychopharmacology at the Royal Free Hospital.

The Company has a strong senior management team and Board team including Joseph Colliver FCA as Chief Financial Officer and a Board Director, and Jonathan Wearing, a seasoned City corporate financier, as Chairman. Dr Nick Horniman, Director of Regulatory Affairs, has over thirty years of experience in the veterinary industry and he co-ordinates the Group’s ongoing relationships with regulators such as the Home Office, Food Standards Agency (FSA) and the Veterinary Medicines Directorate (VMD). He is also investigating the significant opportunities for medicinal cannabis and CBD products in the pet and equine markets. Chris Jones, a retail management professional who was instrumental in building the Phones 4U chain, leads the team developing the Goodbody wellness centres, which will offer customers a variety of high-quality CBD products.

Sativa’s smart-sourcing strategy enables it to define the crucial factors of seed strain, growing techniques and environment, along with extraction methods, all of which are imperative to the quality of the end-product. Phytovista Laboratories confirms the cannabinoid profile and quality of each batch on delivery to ensure that it is regulatorily compliant, is free of unwanted chemical elements, and is of proven origin. The commercial off-take agreements that the Company is entering in to will contribute to quality assurance, forecasted forward quantities of supply, consistency, and pre-determined pricing, rather than spot pricing.

The Group’s activities include the Sativa Foundation, which awards research grants to academic institutions in order to further research & development into the efficacy of the full spectrum of cannabinoids. In April 2019 the Company entered into a three-year research agreement with King’s College London to research the impact of cannabinoids on inflammation and respiratory diseases.

Sativa has invested in two Canadian-based businesses, pharmaceutical company Veritas Pharma Inc. and a Rapid Dose Therapeutics Inc. Both of these provide Sativa with valuable know-how alongside their investment potential. The Company also has a 60% share of a joint venture with Germany’s Lexamed GmbH, providing a foothold into the German market.